I covered Akero Therapeutics (NASDAQ: AKRO ) in May last year when we were awaiting data from the phase 2b SYMMETRY study. Since then, two events negative for the stock have taken place. One, poor SYMMETRY data, and two, Madrigal’s (About the TPT serviceThanks for reading. At the Total Pharma Tracker, we offer the following:-Our Android app and website features a set of tools for DIY investors, including a work-in-progress software where you can enter any ticker and get extensive curated research material.  ...